Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1986 Dec;56(6):544–553. doi: 10.1136/hrt.56.6.544

Effects of verapamil on haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy.

P T Wilmshurst, D S Thompson, S M Juul, B S Jenkins, M M Webb-Peploe
PMCID: PMC1216402  PMID: 3801246

Abstract

The effect of 20 mg dose of intravenous verapamil was studied over a range of heart rates in 12 patients with hypertrophic cardiomyopathy. Six patients had an appreciable left ventricular outflow tract gradient and six did not. The drug reduced myocardial oxygen consumption in proportion to a reduction in the development of left ventricular pressure. The negative inotropic effect of verapamil was counteracted by the drug's non-specific vasodilator activity, so that cardiac index was unaltered at any heart rate and as a result myocardial efficiency was unaffected by the drug. Verapamil did not consistently alter myocardial metabolism. Some patients showed improvement in anaerobic myocardial metabolism after verapamil but an equal number showed impairment of lactate metabolism. It was not possible to predict from clinical features, echocardiographic findings, or haemodynamic variables measured before administration of verapamil which patients would demonstrate haemodynamic or metabolic improvement after the drug. In this short term study no mechanism was demonstrated by which patients with hypertrophic cardiomyopathy might obtain a consistent improvement from treatment with verapamil.

Full text

PDF
544

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson D. M., Raff G. L., Ports T. A., Brundage B. H., Parmley W. W., Chatterjee K. Hypertrophic obstructive cardiomyopathy. Effects of acute and chronic verapamil treatment on left ventricular systolic and diastolic function. Br Heart J. 1984 May;51(5):523–529. doi: 10.1136/hrt.51.5.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bonow R. O., Frederick T. M., Bacharach S. L., Green M. V., Goose P. W., Maron B. J., Rosing D. R. Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. Am J Cardiol. 1983 May 1;51(8):1386–1391. doi: 10.1016/0002-9149(83)90317-x. [DOI] [PubMed] [Google Scholar]
  3. Bonow R. O., Ostrow H. G., Rosing D. R., Cannon R. O., 3rd, Lipson L. C., Maron B. J., Kent K. M., Bacharach S. L., Green M. V. Effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy: pressure-volume analysis with a nonimaging scintillation probe. Circulation. 1983 Nov;68(5):1062–1073. doi: 10.1161/01.cir.68.5.1062. [DOI] [PubMed] [Google Scholar]
  4. Chatterjee K., Raff G., Anderson D., Parmley W. W. Hypertrophic cardiomyopathy--therapy with slow channel inhibiting agents. Prog Cardiovasc Dis. 1982 Nov-Dec;25(3):193–210. doi: 10.1016/0033-0620(82)90016-0. [DOI] [PubMed] [Google Scholar]
  5. Goodwin J. F. The frontiers of cardiomyopathy. Br Heart J. 1982 Jul;48(1):1–18. doi: 10.1136/hrt.48.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kaltenbach M., Hopf R., Kober G., Bussmann W. D., Keller M., Petersen Y. Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J. 1979 Jul;42(1):35–42. doi: 10.1136/hrt.42.1.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kober G., Schmidt-Moritz A., Hopf R., Kaltenbach M. Long-term treatment of hypertrophic obstructive cardiomyopathy--usefulness of verapamil. Eur Heart J. 1983 Nov;4 (Suppl F):165–174. doi: 10.1093/eurheartj/4.suppl_f.165. [DOI] [PubMed] [Google Scholar]
  8. Rosing D. R., Condit J. R., Maron B. J., Kent K. M., Leon M. B., Bonow R. O., Lipson L. C., Epstein S. E. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration. Am J Cardiol. 1981 Sep;48(3):545–553. doi: 10.1016/0002-9149(81)90086-2. [DOI] [PubMed] [Google Scholar]
  9. Rosing D. R., Kent K. M., Borer J. S., Seides S. F., Maron B. J., Epstein S. E. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. Circulation. 1979 Dec;60(6):1201–1207. doi: 10.1161/01.cir.60.6.1201. [DOI] [PubMed] [Google Scholar]
  10. Rosing D. R., Kent K. M., Maron B. J., Epstein S. E. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Circulation. 1979 Dec;60(6):1208–1213. doi: 10.1161/01.cir.60.6.1208. [DOI] [PubMed] [Google Scholar]
  11. Thompson D. S., Naqvi N., Juul S. M., Coltart D. J., Jenkins B. S., Webb-Peploe M. M. Haemodynamic and metabolic effects of atenolol in patients with angina pectoris. Br Heart J. 1980 Jun;43(6):668–679. doi: 10.1136/hrt.43.6.668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Thompson D. S., Wilmshurst P., Juul S. M., Waldron C. B., Jenkins B. S., Coltart D. J., Webb-Peploe M. M. Pressure-derived indices of left ventricular isovolumic relaxation in patients with hypertrophic cardiomyopathy. Br Heart J. 1983 Mar;49(3):259–267. doi: 10.1136/hrt.49.3.259. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES